| Dr Joshua Arthur Mcdonald, PHARMD | |
|
390 N Main St, Bountiful, UT 84010-6046 | |
| (801) 397-6400 | |
| Not Available |
| Full Name | Dr Joshua Arthur Mcdonald |
|---|---|
| Gender | Male |
| Speciality | Pharmacist - Ambulatory Care |
| Location | 390 N Main St, Bountiful, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164195590 | NPI | - | NPPES |
| 11327246-0701 | Other | UT | UTAH STATE BOARD OF PHARMACY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P2201X | Pharmacist - Ambulatory Care | 11327246-0701 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joshua Arthur Mcdonald, PHARMD 360 S 400 W Apt 237, Salt Lake City, UT 84101-1971 Ph: (319) 981-0384 | Dr Joshua Arthur Mcdonald, PHARMD 390 N Main St, Bountiful, UT 84010-6046 Ph: (801) 397-6400 |
News Archive
AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.
Varian Medical Systems and Flatiron Health today announced a strategic alliance to develop the next generation of cloud-based, electronic health record (EHR), data analytics and decision support software for cancer care providers around the world.
Antibiotic resistance is poised to spread globally among bacteria frequently implicated in respiratory and urinary infections in hospital settings, according to new research at Washington University School of Medicine in St. Louis.
University of North Carolina at Chapel Hill researchers have announced study results finding that a formulation of three-beaded extended-release carbamazepine capsules (ERC-CBZ) was effective, safe and tolerable in the treatment of bipolar I disorder
New, long-term results from a clinical trial presented at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association of the Study of Lung Cancer (IASLC) show that MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic), an immune-boosting treatment for lung cancer patients, reduces the risk of relapse after surgery - to the same extent as chemotherapy but without the side-effects of chemotherapy.
› Verified 6 days ago
Dr. Jeffrey David Robinson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 515 W 500 S, Bountiful, UT 84010 Phone: 801-294-1907 | |
Kort H. Delost, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 47 E 500 S, Bountiful, UT 84010 Phone: 801-295-3463 Fax: 801-298-8223 | |
Scott Turpin, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 573 W 100 N, Bountiful, UT 84010 Phone: 801-299-3968 Fax: 801-299-3965 | |
Christopher James Buckel, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 555 S 200 W, Bountiful, UT 84010 Phone: 801-397-7833 | |
Meiqi Jiang, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 515 S 500 W, Bountiful, UT 84010 Phone: 801-294-9107 | |
Dr. Clara Jaklyn Ashton, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1507 N 150 W, Bountiful, UT 84010 Phone: 801-635-9367 | |
Jason Chan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 261 S Moss Hill Dr, Bountiful, UT 84010 Phone: 801-840-4350 Fax: 801-840-4357 |